File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A small nonerythropoietic helix B surface peptide based upon erythropoietin structure is cardioprotective against ischemic myocardial damage

TitleA small nonerythropoietic helix B surface peptide based upon erythropoietin structure is cardioprotective against ischemic myocardial damage
Authors
Issue Date2011
Citation
Molecular Medicine, 2011, v. 17 n. 3-4, p. 194-200 How to Cite?
AbstractStrong cardioprotective properties of erythropoietin (EPO) reported over the last 10 years have been difficult to translate to clinical applications for ischemic cardioprotection owing to undesirable parallel activation of erythropoiesis and thrombogenesis. A pyroglutamate helix B surface peptide (pHBP), recently engineered to include only a part of the EPO molecule that does not bind to EPO receptor and thus, is not erythropoietic, retains tissue protective properties of EPO. Here we compared the ability of pHBP and EPO to protect cardiac myocytes from oxidative stress in vitro and cardiac tissue from ischemic damage in vivo. HBP, similar to EPO, increased the reactive oxygen species (ROS) threshold for induction of the mitochondrial permeability transition by 40%. In an experimental model of myocardial infarction induced by permanent ligation of a coronary artery in rats, a single bolus injection of 60 μg/kg of pHBP immediately after coronary ligation, similar to EPO, reduced apoptosis in the myocardial area at risk, examined 24 h later, by 80% and inflammation by 34%. Myocardial infarction (MI) measured 24 h after coronary ligation was similarly reduced by 50% in both pHBP- and EPO-treated rats. Two wks after surgery, left ventricular remodeling (ventricular dilation) and functional decline (fall in ejection fraction) assessed by echocardiography were significantly and similarly attenuated in pHBP- and EPO-treated rats, and MI size was reduced by 25%. The effect was retained during the 6-wk follow-up. A single bolus injection of pHBP immediately after coronary ligation was effective in reduction of MI size in a dose as low as 1 μg/kg, but was ineffective at a 60 μg/kg dose if administered 24 h after MI induction. We conclude that pHBP is equally cardioprotective with EPO and deserves further consideration as a safer alternative to rhEPO in the search for therapeutic options to reduce myocardial damage following blockade of the coronary circulation. © 2011 The Feinstein Institute for Medical Research.
Persistent Identifierhttp://hdl.handle.net/10722/195139
ISSN
2015 Impact Factor: 3.53
2015 SCImago Journal Rankings: 2.372
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorAhmet, I-
dc.contributor.authorTae, H-J-
dc.contributor.authorJuhaszova, M-
dc.contributor.authorRiordon, DR-
dc.contributor.authorBoheler, KR-
dc.contributor.authorSollott, SJ-
dc.contributor.authorBrines, M-
dc.contributor.authorCerami, A-
dc.contributor.authorLakatta, EG-
dc.contributor.authorTalan, MI-
dc.date.accessioned2014-02-25T01:40:13Z-
dc.date.available2014-02-25T01:40:13Z-
dc.date.issued2011-
dc.identifier.citationMolecular Medicine, 2011, v. 17 n. 3-4, p. 194-200-
dc.identifier.issn1076-1551-
dc.identifier.urihttp://hdl.handle.net/10722/195139-
dc.description.abstractStrong cardioprotective properties of erythropoietin (EPO) reported over the last 10 years have been difficult to translate to clinical applications for ischemic cardioprotection owing to undesirable parallel activation of erythropoiesis and thrombogenesis. A pyroglutamate helix B surface peptide (pHBP), recently engineered to include only a part of the EPO molecule that does not bind to EPO receptor and thus, is not erythropoietic, retains tissue protective properties of EPO. Here we compared the ability of pHBP and EPO to protect cardiac myocytes from oxidative stress in vitro and cardiac tissue from ischemic damage in vivo. HBP, similar to EPO, increased the reactive oxygen species (ROS) threshold for induction of the mitochondrial permeability transition by 40%. In an experimental model of myocardial infarction induced by permanent ligation of a coronary artery in rats, a single bolus injection of 60 μg/kg of pHBP immediately after coronary ligation, similar to EPO, reduced apoptosis in the myocardial area at risk, examined 24 h later, by 80% and inflammation by 34%. Myocardial infarction (MI) measured 24 h after coronary ligation was similarly reduced by 50% in both pHBP- and EPO-treated rats. Two wks after surgery, left ventricular remodeling (ventricular dilation) and functional decline (fall in ejection fraction) assessed by echocardiography were significantly and similarly attenuated in pHBP- and EPO-treated rats, and MI size was reduced by 25%. The effect was retained during the 6-wk follow-up. A single bolus injection of pHBP immediately after coronary ligation was effective in reduction of MI size in a dose as low as 1 μg/kg, but was ineffective at a 60 μg/kg dose if administered 24 h after MI induction. We conclude that pHBP is equally cardioprotective with EPO and deserves further consideration as a safer alternative to rhEPO in the search for therapeutic options to reduce myocardial damage following blockade of the coronary circulation. © 2011 The Feinstein Institute for Medical Research.-
dc.languageeng-
dc.relation.ispartofMolecular Medicine-
dc.titleA small nonerythropoietic helix B surface peptide based upon erythropoietin structure is cardioprotective against ischemic myocardial damage-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.2119/molmed.2010.00235-
dc.identifier.pmid21170473-
dc.identifier.scopuseid_2-s2.0-79952853429-
dc.identifier.volume17-
dc.identifier.issue3-4-
dc.identifier.spage194-
dc.identifier.epage200-
dc.identifier.isiWOS:000288586900006-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats